Infect Chemother.  2018 Jun;50(2):153-159. 10.3947/ic.2018.50.2.153.

Cytomegalovirus Colitis during Dasatinib Treatment for Patients with Hematologic Malignancy: Case Series and Literature Review

• Choi JK
• Cho SY
• Choi SM
• Kim GH
• Lee SE
• Lee S
• Kim DW
• Lee DG

• KMID: 2415038
• DOI: http://doi.org/10.3947/ic.2018.50.2.153

Abstract

Dasatinib, a tyrosine kinase inhibitor, is widely used for patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Although the drug has a potent immunosuppressive effect, infectious complications during dasatinib treatment have been reported rarely. We describe five patients who developed cytomegalovirus (CMV) colitis during dasatinib treatment, in whom the colitis was initially confused with other causes. The patients, three with chronic myeloid leukemia, and two with acute lymphoblastic leukemia, were diagnosed with CMV colitis based on endoscopic and histologic findings. The patients who examined blood CMV polymerase chain reaction were all positive. The patients received antiviral therapy in the form of either ganciclovir or valganciclovir, and the overall treatment outcome was fair. These cases suggest that physicians should consider the possibility of CMV reactivation when treating diarrhea and/or hematochezia in patients on dasatinib.

Keyword

Cytomegalovirus; Colitis; Dasatinib

MeSH Terms

Colitis*
Cytomegalovirus*
Dasatinib*
Diarrhea
Ganciclovir
Gastrointestinal Hemorrhage
Hematologic Neoplasms*
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Polymerase Chain Reaction
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Protein-Tyrosine Kinases
Treatment Outcome
Dasatinib
Ganciclovir
Protein-Tyrosine Kinases